Pharmacokinetic/pharmacodynamic modeling of ketoprofen and flunixin at piglet castration and tail-docking.


Journal

Journal of veterinary pharmacology and therapeutics
ISSN: 1365-2885
Titre abrégé: J Vet Pharmacol Ther
Pays: England
ID NLM: 7910920

Informations de publication

Date de publication:
Sep 2022
Historique:
revised: 17 05 2022
received: 09 10 2021
accepted: 10 06 2022
pubmed: 15 7 2022
medline: 8 9 2022
entrez: 14 7 2022
Statut: ppublish

Résumé

This study performed population-pharmacokinetic/pharmacodynamic (pop-PK/PD) modeling of ketoprofen and flunixin in piglets undergoing routine castration and tail-docking, utilizing previously published data. Six-day-old male piglets (8/group) received either ketoprofen (3.0 mg/kg) or flunixin (2.2 mg/kg) intramuscularly. Two hours post-dose, piglets were castrated and tail docked. Inhibitory indirect response models were developed utilizing plasma cortisol or interstitial fluid prostaglandin E2 (PGE2) concentration data. Plasma IC50 for ketoprofen utilizing PGE2 as a biomarker was 1.2 μg/ml, and ED50 for was 5.83 mg/kg. The ED50 calculated using cortisol was 4.36 mg/kg; however, the IC50 was high, at 2.56 μg/ml. A large degree of inter-individual variability (124.08%) was also associated with the cortisol IC50 following ketoprofen administration. IC50 for flunixin utilizing cortisol as a biomarker was 0.06 μg/ml, and ED50 was 0.51 mg/kg. The results show that the currently marketed doses of ketoprofen (3.0 mg/kg) and flunixin (2.2 mg/kg) correspond to drug responses of 33.97% (ketoprofen-PGE2), 40.75% (ketoprofen-cortisol), and 81.05% (flunixin-cortisol) of the maximal possible responses. Given this information, flunixin may be the best NSAID to use in mitigating castration and tail-docking pain at the current label dose.

Identifiants

pubmed: 35833463
doi: 10.1111/jvp.13083
pmc: PMC9541024
doi:

Substances chimiques

Anti-Inflammatory Agents, Non-Steroidal 0
flunixin 356IB1O400
Ketoprofen 90Y4QC304K
Dinoprostone K7Q1JQR04M
Clonixin V7DXN0M42R
Hydrocortisone WI4X0X7BPJ

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

450-466

Subventions

Organisme : National Pork Board
Organisme : USDA/NIFA Food Animal Residue Avoidance Databank (FARAD) program

Informations de copyright

© 2022 The Authors. Journal of Veterinary Pharmacology and Therapeutics published by John Wiley & Sons Ltd.

Références

BMC Vet Res. 2013 Aug 13;9:165
pubmed: 23941181
Animal. 2012 Sep;6(9):1469-75
pubmed: 23031520
Pain. 2014 Sep;155(9):1861-1870
pubmed: 24973718
J Anim Sci. 2005 Jan;83(1):216-22
pubmed: 15583062
Animal. 2011 Jun;5(8):1237-46
pubmed: 22440176
J Vet Pharmacol Ther. 2008 Jun;31(3):246-52
pubmed: 18471146
J Vet Pharmacol Ther. 2014 Aug;37(4):354-66
pubmed: 24628410
J Vet Pharmacol Ther. 1999 Dec;22(6):349-59
pubmed: 10651463
Clin Pharmacokinet. 1998 Apr;34(4):323-33
pubmed: 9571304
Aust Vet J. 2020 Jun;98(6):256-263
pubmed: 32096229
Front Vet Sci. 2020 Feb 20;7:82
pubmed: 32154277
Chirality. 1993;5(8):589-95
pubmed: 8305286
Animal. 2013 Jul;7(7):1158-62
pubmed: 23388116
Rheumatology (Oxford). 2007 Jun;46(6):911-9
pubmed: 17459958
Vet Anaesth Analg. 2018 Nov;45(6):849-857
pubmed: 30122634
J Clin Pharmacol. 1998 Dec;38(S1):3S-10S
pubmed: 9882076
J Vet Pharmacol Ther. 2011 Apr;34(2):153-9
pubmed: 21395606
Drugs. 1996;52 Suppl 5:13-23
pubmed: 8922554
Am J Vet Res. 2001 Nov;62(11):1755-60
pubmed: 11703020
J Vet Pharmacol Ther. 2018 Apr;41(2):314-323
pubmed: 29143334
PLoS One. 2014 Dec 01;9(12):e113678
pubmed: 25437866
J Vet Pharmacol Ther. 2019 Sep;42(5):572-579
pubmed: 31353535
Anim Health Res Rev. 2014 Jun;15(1):14-38
pubmed: 25605277
Vet Rec. 1995 Oct 21;137(17):428-31
pubmed: 8560701
J Vet Pharmacol Ther. 2003 Apr;26(2):139-50
pubmed: 12667184
Chirality. 1995;7(8):586-97
pubmed: 8593252
Front Vet Sci. 2018 Nov 26;5:299
pubmed: 30534552
J Vet Pharmacol Ther. 2022 Sep;45(5):450-466
pubmed: 35833463
J Anim Sci. 2012 Jul;90(7):2211-21
pubmed: 22266989
J Pharmacokinet Biopharm. 1993 Aug;21(4):457-78
pubmed: 8133465
Anim Health Res Rev. 2014 Jun;15(1):39-62
pubmed: 25605278
J Vet Pharmacol Ther. 2014 Feb;37(1):43-52
pubmed: 23614639
Pharmacol Res. 2005 Oct;52(4):302-6
pubmed: 15939622
PLoS One. 2021 Nov 30;16(11):e0254409
pubmed: 34847143
Equine Vet J. 1995 Jul;27(4):247-56
pubmed: 8536660
J Vet Pharmacol Ther. 2016 Feb;39(1):32-9
pubmed: 25958925
Front Vet Sci. 2016 Nov 28;3:108
pubmed: 27965968
J Vet Pharmacol Ther. 2004 Dec;27(6):479-90
pubmed: 15601442
Vet Anaesth Analg. 2010 Jul;37(4):367-74
pubmed: 20636569
J Vet Pharmacol Ther. 2011 Aug;34(4):338-49
pubmed: 20950352
Br J Pharmacol. 2005 Nov;146(5):642-53
pubmed: 16113689
J Pharmacol Exp Ther. 1998 Dec;287(3):969-74
pubmed: 9864281
J Vet Pharmacol Ther. 1996 Dec;19(6):466-74
pubmed: 8971676

Auteurs

Emma Nixon (E)

Department of Population Health and Pathobiology, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina, USA.

Jason T Chittenden (JT)

Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.

Ronald E Baynes (RE)

Department of Population Health and Pathobiology, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina, USA.

Kristen M Messenger (KM)

Department of Molecular Biomedical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina, USA.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH